Saturday 17 October 2026
Export UTHR’s income statement to Excel — free account
United Therapeutics Corporation
UTHR Healthcare Drug Manufacturers Specialty & Generic
United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024. In the quarter to June 2026, revenue fell 1.92%, EPS grew 14.0% and free cash flow grew 58.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
533.12
8.39
−1.55%
Follow UTHR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
16.14 | 13.34 | 10.80 | 17.07 | 20.40 | 13.03 | 0.00 | 8.01 | 15.88 | 8.89 |
Piotroski F-Score |
8 | 9 | 5 | 7 | 6 | 6 | 1 | 7 | 3 | 6 |
P/S ratio |
6.78 | 5.54 | 4.57 | 6.42 | 5.76 | 4.52 | 2.66 | 2.91 | 3.87 | 3.94 |
Altman Z-Score |
19.55 | 13.29 | 7.73 | 8.71 | 7.13 | 5.69 | 3.87 | 7.84 | 8.36 | 12.17 |
P/FCF ratio |
20.85 | 14.83 | 14.33 | 18.89 | 20.55 | 9.67 | 0.00 | 8.05 | 17.10 | 10.50 |
Altman Z″-Score (non-manufacturers) |
16.93 | 14.60 | 11.68 | 11.14 | 9.44 | 9.12 | 7.37 | 12.54 | 10.25 | 13.66 |
Beneish M-Score |
(2.26) | (2.52) | (2.04) | (2.47) | (2.29) | (2.66) | (2.76) | (2.99) | (2.14) | (2.11) |
P/Operating CF |
62.35 | 46.74 | 70.60 | 97.01 | 55.57 | 53.16 | 37.64 | 55.47 | (77.92) | 38.60 |
P/B ratio |
3.04 | 2.47 | 1.78 | 2.59 | 2.45 | 1.98 | 1.39 | 1.70 | 3.18 | 3.41 |
Price to Tangible BV |
3.09 | 2.52 | 1.81 | 2.62 | 2.48 | 2.07 | 1.47 | 1.81 | 3.25 | 3.47 |
EV/Sales |
5.96 | 4.55 | 3.59 | 5.50 | 5.23 | 3.99 | 2.22 | 2.35 | 3.63 | 3.29 |
EV/EBITDA |
12.02 | 9.02 | 6.74 | 10.33 | 14.56 | 9.21 | 0.00 | 4.54 | 7.40 | 4.81 |
EV/Operating CF |
12.15 | 9.86 | 8.53 | 13.27 | 14.75 | 7.84 | (15.60) | 4.91 | 13.20 | 8.17 |
EV/FCF |
18.32 | 12.16 | 11.24 | 16.17 | 18.68 | 8.54 | (10.90) | 6.49 | 16.01 | 8.76 |
Quick Ratio |
5.83 | 4.80 | 4.07 | 8.91 | 6.97 | 6.16 | 3.54 | 5.75 | 2.75 | 3.81 |
Current Ratio |
6.60 | 5.25 | 4.41 | 9.85 | 7.61 | 6.70 | 4.03 | 6.39 | 3.26 | 4.29 |
Net Debt/EBITDA |
(1.85) | (2.05) | (1.85) | (1.98) | (1.87) | (1.61) | 4.49 | (1.39) | (0.80) | (0.96) |
Debt/Assets |
0.00% | 4.07% | 9.77% | 13.24% | 15.48% | 17.33% | 21.72% | 7.35% | 8.68% | 0.00% |
Debt/Equity |
0.00 | 0.05 | 0.12 | 0.17 | 0.20 | 0.24 | 0.31 | 0.09 | 0.12 | 0.00 |
Asset Turnover |
0.42 | 0.40 | 0.35 | 0.35 | 0.34 | 0.35 | 0.40 | 0.52 | 0.66 | 0.71 |
Operating CF/Net income |
1.17 | 1.11 | 0.99 | 1.10 | 1.26 | 1.47 | 1.98 | 1.32 | 1.13 | 0.90 |
Capex/Depreciation |
(6.14) | (3.40) | (4.33) | (2.71) | (2.42) | (1.14) | (1.82) | (5.14) | (2.52) | (1.20) |
Interest Coverage |
76.54 | 32.10 | 19.98 | 30.24 | 29.89 | 25.26 | (4.24) | 57.94 | 90.54 | 272.23 |
| 19.71% | 19.23% | 18.27% | 16.61% | 12.94% | 16.67% | (3.75%) | 24.10% | 21.14% | 41.50% | |
| 17.51% | 16.45% | 14.91% | 12.97% | 9.73% | 12.07% | (2.86%) | 18.76% | 16.06% | 31.65% | |
ROIC |
22.34% | 24.75% | 20.07% | 22.20% | 12.28% | 15.72% | (5.47%) | 31.02% | 35.76% | 82.89% |
Return on Tangible Assets |
27.40% | 27.42% | 25.97% | 18.66% | 17.00% | 19.99% | (4.88%) | 26.89% | 26.98% | 45.13% |
Average Days of Receivables |
40.16 | 35.43 | 43.74 | 41.55 | 43.03 | 38.73 | 38.14 | 39.40 | 62.85 | 48.97 |
Research and Development Expense of Revenue |
17.28% | 16.72% | 17.53% | 16.68% | 32.04% | 24.12% | 81.63% | 21.99% | 15.34% | 9.23% |
Selling, General and Administrative Expense of Revenue |
23.75% | 24.66% | 20.50% | 24.90% | 27.71% | 28.58% | 23.21% | 16.33% | 19.13% | 19.81% |
Intangible Assets out of Total Assets |
0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.03 | 0.04 | 0.05 | 0.02 | 0.01 |
Share Based Compensation of Revenue |
4.64% | 5.00% | 1.68% | 5.52% | 8.22% | 11.04% | 3.13% | (1.62%) | 4.26% | 0.76% |
Graham Net Nets |
0.14 | 0.19 | 0.22 | 0.17 | 0.11 | 0.14 | 0.19 | 0.24 | 0.10 | 0.15 |
Graham Number |
329.81 | 291.28 | 246.16 | 194.87 | 144.95 | 141.90 | 0.00 | 140.06 | 101.42 | 124.12 |
Earnings Yield |
6.19% | 7.50% | 9.26% | 5.86% | 4.90% | 7.68% | (2.75%) | 12.49% | 6.30% | 11.25% |
Free Cash Flow Yield |
4.80% | 6.74% | 6.98% | 5.30% | 4.87% | 10.34% | (7.66%) | 12.43% | 5.85% | 9.52% |
Revenue per Share |
71.84 | 63.66 | 49.73 | 42.56 | 37.54 | 33.56 | 33.08 | 37.42 | 39.21 | 36.50 |
Operating CF per Share |
35.24 | 29.36 | 20.90 | 17.64 | 13.32 | 17.10 | (4.72) | 17.89 | 10.78 | 14.69 |
Capex per Share |
(11.87) | (5.45) | (4.92) | (3.05) | (2.69) | (1.29) | (1.91) | (4.24) | (1.77) | (0.87) |
Free Cash Flow per Share |
23.37 | 23.91 | 15.97 | 14.59 | 10.63 | 15.81 | (6.63) | 13.66 | 9.00 | 13.83 |
Cash per Share |
65.92 | 72.28 | 63.98 | 62.39 | 43.00 | 41.52 | 33.92 | 32.55 | 21.08 | 23.99 |
Shareholders Equity per Share |
160.19 | 142.57 | 127.88 | 105.42 | 88.17 | 76.81 | 63.48 | 64.11 | 47.77 | 42.27 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
160.19 | 142.57 | 127.88 | 105.42 | 88.17 | 76.81 | 63.48 | 64.11 | 47.77 | 42.27 |
Free Cash Flow |
1,035.20 | 1,080.60 | 747.60 | 663.70 | 477.40 | 698.80 | (290.30) | 594.00 | 396.20 | 605.60 |
Working Capital |
3,141.90 | 3,135.80 | 2,746.60 | 3,037.10 | 2,018.20 | 1,843.90 | 1,401.50 | 1,491.40 | 1,003.20 | 1,092.30 |
Capital Expenditures |
(526.00) | (246.50) | (230.40) | (138.80) | (120.80) | (56.90) | (83.70) | (184.40) | (78.00) | (38.00) |
Net Current Asset Value |
2,918.70 | 2,953.90 | 2,368.80 | 2,132.50 | 1,113.40 | 947.40 | 731.50 | 1,155.60 | 670.30 | 950.50 |
EV/EBIT |
12.71 | 9.50 | 7.04 | 10.87 | 15.87 | 9.98 | 0.00 | 4.74 | 7.68 | 4.95 |
Capex to Sales |
0.17 | 0.09 | 0.10 | 0.07 | 0.07 | 0.04 | 0.06 | 0.11 | 0.05 | 0.02 |
Price to Operating Income |
14.46 | 11.58 | 8.98 | 12.69 | 17.45 | 11.30 | 0.00 | 5.88 | 8.20 | 5.94 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.05 | 0.06 | 0.05 | 0.06 | 0.06 | 0.07 | 0.06 | 0.05 | 0.06 | 0.06 |
Cash ROIC |
10.33% | 10.79% | 7.72% | 7.87% | 7.14% | 11.59% | (5.67%) | 13.33% | 12.08% | 20.87% |
Accounts Receivable Turnover |
10.11 | 10.31 | 9.32 | 9.24 | 9.47 | 9.61 | 8.86 | 6.89 | 6.74 | 7.85 |
Accounts Payable Turnover |
0.92 | 0.96 | 0.98 | 0.75 | 0.68 | 0.64 | 0.75 | 1.18 | 0.77 | 0.70 |
Inventory Turnover |
2.25 | 2.30 | 2.41 | 1.55 | 1.36 | 1.20 | 1.21 | 1.90 | 1.02 | 0.80 |
Average Days of Payables |
463.37 | 406.01 | 422.41 | 553.52 | 520.24 | 631.41 | 460.60 | 305.12 | 590.84 | 523.15 |
Days of Inventory on Hand |
173.86 | 186.09 | 158.47 | 245.58 | 279.49 | 292.07 | 289.89 | 185.53 | 372.60 | 502.06 |
Average Receivables |
314.75 | 279.10 | 249.65 | 209.55 | 178.05 | 154.40 | 163.55 | 236.40 | 255.80 | 203.65 |
Average Payables |
416.25 | 321.25 | 263.95 | 202.25 | 180.80 | 167.70 | 157.25 | 168.60 | 137.65 | 103.80 |
Average Inventory |
170.50 | 134.85 | 106.90 | 97.90 | 90.15 | 89.95 | 97.20 | 104.45 | 103.95 | 90.65 |
Average Assets |
7,622.00 | 7,265.50 | 6,605.75 | 5,606.80 | 4,892.05 | 4,264.20 | 3,657.20 | 3,140.20 | 2,602.50 | 2,255.00 |
Average Common Equity |
6,770.10 | 6,214.40 | 5,390.75 | 4,377.80 | 3,677.05 | 3,087.80 | 2,784.50 | 2,445.20 | 1,976.55 | 1,719.95 |
Columns are period end dates